# Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery

> **NCT02137161** · PHASE4 · COMPLETED · sponsor: **Azienda USL Reggio Emilia - IRCCS** · enrollment: 62 (actual)

## Conditions studied

- Cataract
- Pseudoexfoliation Syndrome

## Interventions

- **DRUG:** Dexamethasone+Tobramycin eye drop
- **DRUG:** Bromfenac eye drop

## Key facts

- **NCT ID:** NCT02137161
- **Lead sponsor:** Azienda USL Reggio Emilia - IRCCS
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137161, "Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02137161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*